J
José Rodrigues Pereira
Researcher at University of Texas MD Anderson Cancer Center
Publications - 43
Citations - 17727
José Rodrigues Pereira is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 24, co-authored 40 publications receiving 17053 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more
TL;DR: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.
Journal ArticleDOI
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Nick Thatcher,Alex R. Chang,Purvish M. Parikh,José Rodrigues Pereira,Tudor Ciuleanu,Joachim von Pawel,Sumitra Thongprasert,Eng Huat Tan,Kristine Pemberton,Venice Archer,Kevin H Carroll +10 more
TL;DR: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population, and there was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.
Journal ArticleDOI
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial
Jean-Yves Douillard,Rafael Rosell,Mario De Lena,Francesco Carpagnano,Rodryg Ramlau,Jose Luis Gonzáles-Larriba,Tomasz Grodzki,José Rodrigues Pereira,Alain Le Groumellec,Vito Lorusso,Claude Clary,Antoni Torres,Jabrail Dahabreh,Pierre Jean Souquet,Julio Astudillo,Pierre Fournel,Angel Artal-Cortes,Jacek Jassem,Leona Koubkova,Patricia His,Marcello Riggi,Patrick Hurteloup +21 more
TL;DR: Adjuvant vinorelbine plus cisplatin extends survival in patients with completely resected NSCLC, better defining indication of adjuvant chemotherapy.
Journal ArticleDOI
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker,José Rodrigues Pereira,Aleksandra Szczesna,Joachim von Pawel,Maciej Krzakowski,Rodryg Ramlau,Ihor Vynnychenko,Keunchil Park,Chih Teng Yu,Valentyn Ganul,Jae Kyung Roh,Emilio Bajetta,Kenneth J. O'Byrne,Filippo de Marinis,Wilfried Eberhardt,Thomas Goddemeier,M. Emig,Ulrich Gatzemeier +17 more
TL;DR: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer.